Dysregulated microRNA (miRNA) mediate malignant phenotypes, including metabolic reprogramming. By performing an integrative analysis of miRNA and metabolome data for the NCI-60 cell line panel, we identified an miRNA cluster strongly associated with both c-Myc expression and global metabolic variation. Within this cluster the cancer-associated and cardioprotective miR-22 was shown to repress fatty acid synthesis and elongation in tumour cells by targeting ATP citrate lyase and fatty acid elongase 6, as well as impairing mitochondrial one-carbon metabolism by suppression of methylene tetrahydrofolate dehydrogenase/cyclohydrolase. Across several data sets, expression of these target genes were associated with poorer outcomes in breast cancer patients. Importantly, a beneficial effect of miR-22 on clinical outcomes in breast cancer was shown to depend on the expression levels of the identified target genes, demonstrating the relevance of miRNA/mRNA interactions to disease progression in vivo. Our systematic analysis establishes miR-22 as a novel regulator of tumour cell metabolism, a function that could contribute to the role of this miRNA in cellular differentiation and cancer development. Moreover, we provide a paradigmatic example of effect modification in outcome analysis as a consequence of miRNA-directed gene targeting, a phenomenon that could be exploited to improve patient prognosis and treatment.
INTRODUCTION
Cancer cells exhibit altered metabolic behaviour compared with non-cancerous cells, enabling them to survive in nutrient-deprived, poorly vascularized tumour regions and to generate the macromolecules required for rapid division. 1, 2 These metabolic alterations include enhanced synthesis of nucleotides and lipids from glucose and glutamine, increased nutrient uptake and acid export, and amplified choline metabolism. The metabolic reprogramming of cancer cells is a highly complex process affected by the identity of genetic lesions, interactions with the microenvironment and cell context. Substantial research now focuses on elucidating the molecular mechanisms underlying the cancer metabolic phenotype. Improved knowledge of these mechanisms could facilitate patient diagnosis/prognosis and the identification of novel targeted and synthetically lethal metabolic interventions. [3] [4] [5] The function of mature microRNAs (miRNAs) is to fine-tune the expression of their target genes by causing mRNA degradation and/or translational repression, with each miRNA potentially regulating hundreds of proteins. 6 It is now recognized that miRNAs have considerable potential as stratification markers and therapeutic targets in cancer. Several miRNAs have been attributed oncogenic or tumour-suppressive properties [7] [8] [9] and miRNA signatures are prognostic in human cancers. 10, 11 Some studies have also identified specific miRNAs involved in regulating key aspects of cancer metabolism such as glycolysis, [12] [13] [14] glutaminolysis 15 and proline metabolism, 16 although possibly many more miRNA metabolic regulators remain to be discovered. Consequently, identification of the key miRNAs targeting metabolic enzymes or their effectors in tumours could enhance understanding of the mechanisms driving metabolic reprogramming of cancer. The functional linking of miRNAs to metabolic phenotypes is hindered by the high false-positive and false-negative rates of in-silico target predictions and the laborious/time-consuming process of experimentally verifying miRNA:mRNA interactions. Here we explored the systematic analysis of the global relationship between miRNA variation and metabolomic profiles as a method to prioritize miRNAs for further experimental investigation. The bidirectional orthogonal projections to latent structures (O2-PLS) algorithm is a multivariate regression model for integrating and defining predictive co-variation between 'omic' data sets. 17 Several applications of the O2-PLS methodology have been successfully carried out for combining transcriptomic and metabolomic data, 18 proteomic and metabolomic data, 19 and data on different classes of lipid metabolites. 20 In this study we performed O2-PLS analysis on metabolomics 21 and miRNA expression 22 profiles that had been generated previously for the NCI-60 cell line panel, a collection of lines originating from nine different tumour types. Our systematic analysis led us to the identification of miR-22 as an important regulator of cancer cell metabolism.
1 RESULTS MYC-regulated miRNAs are associated with altered metabolism in the NCI-60 panel of cell lines As a starting point for our analysis, an O2-PLS model was constructed to capture the co-variation between global intracellular metabolite levels across the NCI-60 panel and expression levels of miRNAs predicted to target metabolic genes. By randomly permuting the metabolomic and miRNA profiles associated to each cell line and generating 'null' models (Supplementary Figures S1A-D) , we were able to identify from the model parameters (individual variable Q 2 ) a subset of 13 miRNAs (23 probesets out of 316) and 18 metabolites (out of 154) that were significantly correlated (Figures 1a and b) . These associations were confirmed by direct inspection of the univariate Pearson's correlation coefficients within this subset of molecules (P o 0.05 in 84% of the correlations displayed) (Figure 1c ). The metabolite set identified by this model included intermediates in glycolysis (3-phosphoglycerate), tricarboxylic acid cycle (citrate), one-carbon metabolism (S-adenosylmethionine), lipid (palmitate and cholesterol) and nucleotide metabolism (xanthosine), all pathways known to be significantly perturbed in cancer. The miRNAs identified by our model in the NCI-60 data set included miR-23a/b and let-7a, miRNAs that have previously been identified as important metabolic regulators, 13, 15, 16 verifying the validity of our approach. All of the miRNAs identified by our analysis (miR-17-92 cluster, miR-106-363 cluster, miR-23a/23b, miR-142a-3p and miR-22) have been reported previously to be regulated by the oncogenic transcription factor c-Myc (MYC), 15, [23] [24] [25] consistent with the hypothesis that the transcription factor fine-tunes metabolism through miRNAs. 15, 16 We confirmed a high degree of correlation between MYC expression and the metabolome-associated miRNAs in the NCI-60 panel (Figure 1d ). As the panel is very heterogeneous and includes cell lines from haematological malignancies likely to be specifically driven by MYC expression, we repeated the multivariate analysis including only cell lines derived from solid tumours and obtained a highly coincident set of associated metabolites/miRNAs (Supplementary Figures S1E and F) , albeit Color key and histogram   miR-17  miR-106a  miR-20a  miR-20a  miR-20b  miR-19a  miR-93  miR-93  miR-93  miR-92a  miR-92a  miR-92a  miR-142-3p  miR-22  miR-125b  let-7a  let-7a  miR-24  miR-24  miR-23a  miR-23b miR-23a with lower statistical significance. These observations suggested that a MYC-correlated miRNA module is associated with the metabolic phenotype of cancer cells within the NCI-60 panel, irrespective of tumour site of origin.
The miRNA miR-22 represses de novo fatty acid synthesis and elongation by targeting ACLY and long-chain fatty acid ELOVL6 In our multivariate model, miR-22 showed the most robust association to metabolism (that is, the highest individual Q 2 value) and high individual correlations to metabolites. This miRNA has been proposed to affect cellular proliferation, differentiation and apoptosis via such targets as ERα, p21, TET2, SIRT1, HDAC4 and MYCBP, [25] [26] [27] [28] [29] [30] [31] [32] [33] but direct regulation of metabolism by miR-22 has not been previously reported. Consequently, we focused on investigating the regulatory functions of this miRNA on cancer metabolism. As a strategy to identify metabolic targets of miR-22, we defined the intersection of genes (i) repressed by 41.5-fold following overexpression of miR-22 in both breast MCF-7 (GSE17508) 33 and ovarian ES-2 (GSE16568) 34 cell lines (ii) predicted to be targets of miR-22 by three or more target prediction algorithms (Figure 2a and Supplementary File S1). Predicted direct targets of miR-22 were enriched among genes repressed in both cell lines (7 out of 18; Fisher's exact test, Po 0.01). Among the seven selected genes were MYCBP, a verified miR-22 target, 33 three as-yet uncharacterized genes (C17orf58, PRICKLE4 and PRPF38A) and the nuclear receptor coactivator NCOA1. Significantly, two metabolic enzymes, ATP citrate lyase (ACLY) and elongase 6 (ELOVL6), were identified as putative miR-22 targets. ACLY is a key regulator of tumour cell metabolism catalysing the conversion of citrate into acetyl-CoA for fatty acid or cholesterol synthesis. 35 Depletion of ACLY in cancer cells has also recently been shown to cause accumulation of triglycerides and coincident depletion of ELOVL6. 36 ELOVL6 is a member of a family of enzymes that are rate limiting for the generation of fatty acids beyond 16 carbons and preferentially converts palmitate to stearate. 37 Consequently, miR-22 would be expected to inhibit the pathway of de novo lipid synthesis by repressing ACLY and the elongation of fatty acids by repressing both ACLY and ELOVL6 (Figure 2b) . Genes repressed following miR-22 transfection were significantly enriched for pathways involved in fatty acid synthesis in both MCF-7 and ES-2 cell lines (Supplementary File S2), consistent with this hypothesis.
To study the effect of miR-22 on ACLY and ELOVL6, we transiently overexpressed the miRNA in MCF-7 cells (Supplementary Figures S2A) , a tumour line with low basal levels of this miRNA, and observed repression of mRNA ( Figure 2c ) and protein ( Figure 2d ) for the two genes. Overexpression of the miRNA also suppressed the activity of luciferase reporters containing the wild-type 3′-untranslated region (3′-UTR) of ACLY and ELOVL6, but had no effect when the putative miR-22 interaction site were mutated, implying direct and specific inhibition of these genes (Figure 2e ). To examine the metabolic consequences of the coordinated repression of these two key metabolic enzymes by miR-22, we used isotopomer spectral analysis ( Figure 2f ) and gas chromatography-mass spectrometry (GC-MS) measurements of transesterified palmitate and stearate in MCF7 cells cultured in U-13 C 6 -glucose (Figures 2g and h ) to model the incorporation of glucose-derived carbon into lipids. 38, 39 MiR-22 overexpression caused a consistent reduction in the fraction of de novo-synthesized palmitate and stearate incorporated into lipids (g(t)) after 5 and 48 h incubation with labelled glucose (Figure 2g and Supplementary Figures S3A-C) and reduced the fraction of lipogenic acetyl-CoA derived from glucose after 48 h incubation (Figure 2g ), supporting a link between miR-22 and de novo lipogenesis. We also observed a decrease specifically in the proportion of stearate synthesized by elongation of endogenous palmitate (Figures 2g and h) , consistent with downregulation of ELOVL6. Direct suppression of ACLY and ELOVL6 using small interfering RNA phenocopied the effects of miR-22 on stearate synthesis, providing further evidence that the activity of these enzymes was relevant to the functional effects of this miRNA (Supplementary Figure S4) , The miRNA miR-22 influences one-carbon metabolism by repressing bifunctional MTHFD2 Beyond the role of miR-22 in the regulation of lipid metabolism, we had observed that in the NCI-60 panel the miRNA was strongly anticorrelated to levels of S-adenosylmethionine (Spearman's ρ = − 0.63, P = 0.0002 significant after Bonferroni correction). The synthesis and recycling of S-adenosylmethionine is coupled to folate-dependent one-carbon metabolism; hence, we hypothesized that this miRNA regulated members of this metabolic pathway. Three enzymes of one-carbon metabolism were predicted by at least three prediction algorithms to be targets of miR-22: methylene tetrahydrofolate dehydrogenase/cyclohydrolase (MTHFD2), MAT2A and MTHFR (Supplementary File S1). To investigate the potential regulatory effect of miR-22 on these three enzymes, we examined MCF-7 cells overexpressing the miRNA (Supplementary Figure S2A Figure S2D ). In addition, miR-22 suppressed luciferase activity specifically for wild-type 3′-UTR of MTHFD2, while having no effect on a reporter with a mutated miR-22-binding site, demonstrating direct targeting (Figure 3c ). MTHFD2 is crucial for the regeneration of mitochondrial tetrahydrofolate that is needed for purine synthesis, the S-adenosylmethionine cycle and mitochondrial glycine synthesis 40 ( Figure 3d ). Hence, miR-22-mediated suppression of MTHFD2 activity is likely to alter mitochondrial one-carbon metabolism in cancer cells and to modulate sensitivity to antifolate chemotherapy.
Interactions of miR-22 with its metabolic targets affect clinical outcomes in breast cancer
To evaluate the relevance of our findings to human cancer, we examined gene expression profiles across several publicly available data sets of breast tumours, the cancer with currently the strongest evidence implicating miR-22 deregulation to the development of the disease. 28, 30, 33, 41, 42 In two distinct breast cancer data sets, miR-22 was shown to be significantly negatively correlated to MYC (from The Cancer Genome Atlas (TCGA): ρ = − 0.16, P = 1 × 10 − 8 ; from Farazi et al. 44 : ρ = − 0.25, P = 0.001), similar to previous observations in the NCI-60 cell line panel ( Figure 1d ). We next examined whether miR-22 was associated with expression levels of the metabolic targets identified here (MTHFD2, ACLY and ELOVL6) in breast cancer tissue. In two independent tumour series, 43, 44 levels of the mature miR-22 as determined by miRNA-seq were significantly correlated to mRNA expression of MTHFD2 (Figure 4a ), consistent with regulation of this target gene by miR-22 in vivo. For the other two identified targets, significant correlation was observed in at least one of these data sets ( Figure 4b ). As miR-22 is intragenic, we also considered using the expression levels of the miR-22 host gene (MIR22-HG) as a surrogate marker for the mature miRNA given the much wider availability of transcriptomic data from breast cancer tissue containing probes for this transcript. MIR22-HG and miR-22 were highly positively correlated in TCGA data set (ρ = 0.51, Po 1 × 10
). Consistent with the regulatory effect of miR-22 on ACLY, ELOVL6 and MTHFD2, we observed negative correlations between in vivo expression of MIR22-HG and mRNA levels of all three target genes in several independent data sets ( Figure 4b ). These observations support our hypothesis of miR-22 suppressing these metabolic target genes in human tumours (Figure 4c) .
We next investigated the association between the expression of MIR22-HG, ACLY, ELOVL6 and MTHFD2, and relapse-free survival in breast cancer patients. We found that a combined analysis of relapse-free survival data using a random effects model for these patient cohorts indicated a significant inverse (protective) association between MIR22-HG and relapse rate (Figure 5a , upper versus lower expression tertiles hazard ratio (HR): 0.68, P = 0.001), as well as a positive association between tumour expression of miR-22 target genes and patient outcomes (Figures 5b-d; MTHFD2 HR: 1.58, P = 0.019; ACLY HR: 1.34, P = 0.06; ELOVL6 HR: 1.54, P = 0.004). Kaplan-Meier analyses also indicated a sequential increase in progression rates across tertiles of expression for MTHFD2 and MIR22-HG, whereas in the case of ELOVL6 the exposure-response relationship observed was that the upper tertile was distinct from the middle and lower tertile groups, which were equivalent (Supplementary Figure S5) . A tumour-suppressive role for miR-22 is in agreement with its reported repression of cell proliferation, 25 promotion of cell senescence 30 and activation of apoptosis. 27 In breast cancer specifically, miR-22 has been suggested to block cancer progression by repressing the expression of ERα, 33 CDK6 and SIRT1, 30 EV-1, 41 and CD147. 42 In contrast, a recent report links miR-22 upregulation with epithelial-mesenchymal transition and metastasis in mouse models of breast cancer via suppression of the TET family of methyl cytosine dioxygenases, leading to hypermethylation of the miR-200 promoter. 28 In a related study, repression of TET was proposed to lead to increased haematopoietic stem cell self-renewal, defective differentiation and ultimately myelodysplastic syndrome and leukaemia. 29 In addition, miR-22 has been All data are shown as mean ± s.e.m., n = 3. **P o0.01, ***P o0.001.
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reported to regulate the phosphatase and tensin homologue tumour suppressor gene. 46 Consequently, it is possible that miR-22 can act as both an oncogene or as a tumour suppressor depending on the specific cellular context, including the metabolic microenvironment.
Importantly, the data presented here suggest that another important effect of miR-22 is the suppression of anabolic pathways that contribute to cancer development. MTHFD2 is one of the most highly overexpressed metabolic genes across a wide range of tumour types 47 and is a crucial component of mitochondrial one-carbon metabolism that sustains nucleotide synthesis and high proliferation rates. 48 It may also contribute to antioxidant defence through NADPH generation. 49, 50 Inhibition of ACLY leads to decreased proliferation in cells reliant on de novo lipogenesis 35 and acetyl-coA generated by ACLY also supports histone acetylation associated with regulating gene expression. 51 Upregulation of ELOVL6 has been implicated in the development of breast 52 and liver cancer. 53 Beyond its role in cancer, miR-22 is a highly conserved microRNA throughout animal evolution 54 and analysis of miR-22 expression across multiple tissues indicates that it is one of the most abundantly expressed miRNAs in diverse adult tissues in vivo (Supplementary Figure S11) . miR-22 has recently been characterized as a cardiac and skeletal muscle-enriched miRNA that is upregulated during myocyte differentiation and cardiomyocyte hypertrophy, 32 and its deletion in vivo promotes stress-induced cardiac dilation and contractile dysfunction. 55 In this model, miR-22 may also target other metabolic genes including PGC-1α, PPARα and SIRT1. 56 Our finding that an miRNA can act as an effect modifier of a prognostic gene that it targets is potentially highly significant. It suggests a role for the rational investigation of miRNA/mRNA interaction pairs as combination biomarkers for prognostication or personalized medicine in oncology. Several lines of evidence point to MTHFD2 as a possible target for the development of selective anti-cancer agents 47, 48 and MTHFD2 expression might be a predictive marker for susceptibility to anti-folate chemotherapy. 57, 58 Thus, miR-22 levels may provide an additional, mechanistically justified means to refine MTHFD2-based patient stratification and enrich further the subgroup likely to respond to specific treatments, such as methotrexate. Conversely, it may be possible to avoid unnecessary morbidity in patients unlikely to benefit from a treatment regime associated with a high degree of toxicity.
In conclusion, using an integrative biology approach to the study of cancer cell molecular profiles ('systems oncology'), we have identified a novel mammalian pathway of metabolic regulation involving a ubiquitously expressed miRNA that appears to be relevant to progression in human breast cancer. Our correlative analyses also suggest that the pathway may act downstream of key transcription factors such as MYC; however, we did not test this hypothesis explicitly and further work will be required to resolve the contrasting evidence in the literature with regard to MYC regulation of miR-22. 24, 33, 59 As miRNAs appear to 'fine-tune' activity of multiple targets rather than 'switch off' specific mRNAs, it is likely to be that miR-22 will not uniquely control phenotypic response but rather act as part of a wider, as-yet uncharacterized RNA interaction network, which integrates signals from several pathways. Given the conservation and high abundance of miR-22, the interactions we have proposed may have potential significance in normal physiology. Although the metabolic pathway we have reported may contribute to the proposed functions of miR-22 in cardiac protection, embryogenesis, growth and tumourigenesis, further work will be required to elucidate the true significance of miR-22 in human disease.
MATERIALS AND METHODS

O2-PLS modelling
miRNA normalized log2 expression across the NCI-60 cell panel was downloaded from the NCBI Gene Expression Omnibus (GEO) database (accession number GSE26375). 22 Metabolomic data were downloaded from http://dtp.nci.nih.gov/mtargets/download.html on 28 March 2012. From the initial 1151 miRNA probes, 316 were selected corresponding to miRNAs targeting metabolic genes as defined by Recon1 metabolic reconstruction. 60 Gene-targeting miRNAs were predicted by TargetScan. 61 Levels of 154 identified metabolites were log-transformed and used in the analysis. O2-PLS 17, 62 is an extension of a supervised multivariate analysis method-partial least squares-with an integrated orthogonal signal correction filter that allows prediction in both directions between multivariate matrices X and Y. The miRNA expression and metabolite data were centred and univariate scaled. Sevenfold cross-validation was performed to calculate Q For mRNA and miRNA analysis, reverse transcription was performed using the high-capacity cDNA reverse transcription kit (Applied Biosystems, Warrington, UK) and the miRNA reverse transcription kit (Applied Biosystems), respectively. The quantitative reverse transcriptase-PCR was performed using the TaqManFast advanced master mix and pre-designed TaqMan probes (Applied Biosystems) in the ABI 7500 Real-Time PCR system. Relative miRNA levels were calculated using the ΔΔC T method with U6 RNA used for normalization.
Immunoblotting
Protein was isolated from cells using RIPA buffer (Sigma-Aldrich, Bromborough, UK) and quantified using a BCA assay (Pierce, Cambridge, UK). Monoclonal anti-MTHFD2 (ab56772), anti-MAT2A (ab86424), anti-MTHFR (ab113637), anti-ACLY (ab61762) and anti-ELOVL6 (ab69857) antibodies were purchased from Abcam (Winsford, UK). Monoclonal anti-β-actin (AC-15) antibody was purchased from Sigma-Aldrich. Protein lysates were resolved in 10% acrylamide gels by SDS-polyacrylamide gel electrophoresis and the relative intensities were determined using the ImageJ software (US National Institutes of Health, Bethesda, MD, USA).
Transient transfections of miR-22
The miR-22 mirVana miRNA mimic and mirVana mimic negative control 1 (referred to in figures as the scramble control) were obtained from Applied Biosystems. Transfections were performed using SiPortNeoFx (Applied Biosystems) according to the manufacturer's instructions, with a final concentration of 50 nM for the miRNA mimic/inhibitors and the scramble control. Unless otherwise stated, summary data shown are for n = 3 independent experiments.
RNA silencing of ACLY and ELOVL6
The Silencer Select siACLY, siELOVL6 and negative control 1 (referred to in figures as control) were obtained from Applied Biosystems. Transfections were performed using SiPortNeoFx (Applied Biosystems) according to the manufacturer's instructions, with a final concentration of 50 nM for the miRNA mimic/inhibitors and the scramble control.
Luciferase reporter assay
The ACLY 3′-UTR reporter clone pMirTarget-ACLY (SC211546) and the MTHFD2 3′-UTR reporter clone pMirTarget-MTHFD2 (SC212261) and corresponding reporter clones with base substitutions (pMir Target-ACLY-MUT and pMirTarget-MTHFD2-MUT) were obtained from 
pTK-CLuc (New England Biolabs, Hitchin, UK) containing the Cypridina luciferase gene was cotransfected for the normalization of transfection efficiencies. MCF7 cells were first co-transfected with appropriate plasmids and miRNA mimics in 24-well plates and then collected and lysed for luciferase assays 24 h after transfection. The culture medium was collected for Cypridina luciferase assays. Cells transfected with pMirTarget plasmids were assayed for firefly luciferase using ONE-Glo Luciferase Assay Reagent (Promega, Southampton, UK), whereas cells transfected with GoClone plasmids were assayed for Renilla luciferase using the LightSwitch Assay Reagent (Switchgear Genomics). Control Cypridina luciferase expression from the pTK-CLuc plasmid was assayed using the BioLux Cypridina Luciferase Assay Kit (New England Biolabs). Luminescence was quantified using a Plate Luminometer (Synergy H1, Biotek, Swindon, UK) and the target reporter luciferase activity was normalized by luminescence from Cypridina luciferase. Summary data shown are for n = 3 independent experiments.
13 C-glucose labelling experiments MCF-7 cells that had been transiently transfected with miR-22 miRNA mimic or the negative control mimic were cultured with U-13 C 6 -glucose for 5 or 48 h in 6-well plates (n = 4). MCF-7 cells transfected with siACLY, siELOVL6 or the negative control small interfering RNA were also cultured with U-13 C 6 -glucose for 48 h in 6-well plates (n = 5). After trypsinization, MCF-7 cells were resuspended in minimal essential medium (with 10% fetal bovine serum, 5% non-essential amino acids and 5% penicillin/ streptomycin) and 200k cells were seeded per well and allowed to adhere overnight. Cells were then incubated for 1 h with glucose and glutaminefree Dulbecco's modified Eagle's medium with 5.6 mM 12 C 6 -glucose, 2 mM glutamine, 10% dialysed-fetal bovine serum (BioSera, Brambleside, UK) and 5% penicillin/streptomycin, to equilibrate intracellular metabolites with the media in preparation for addition of the 13 C-labelled carbon source. After 1 hr, the media was replaced with glucose-and glutamine-free Dulbecco's modified Eagle's medium supplemented with 5.6 mM 13 C 6 -glucose, 2 mM glutamine, 10% dialysed-fetal bovine serum (BioSera) and 5% penicillin/ streptomycin, and incubated for 5 or 48 h.
At 5 or 48 h, the media was aspirated and the cell monolayer washed with cold (4°C) Ringer's buffer, which was aspirated before addition of 750 μl of cold (approximately − 70°C) methanol. The methanol-quenched cells were then scraped from the well and the sample was transferred to a clean tube. To increase metabolite recovery, each well was washed with a further 750 μl of cold methanol and pooled with the first sample. The methanol-quenched samples were then dried in a rotary evaporator under reduced pressure. Metabolites were extracted from the methanolquenched cell sample using a dual phase aqueous methanol/chloroform method. The upper aqueous fraction and lower organic fraction were transferred to separate silanized GC-MS vials. Fatty acid esters present in the organic fraction were transesterified with the strong base sodium methoxide, leaving the free fatty acids to be silylated with N-tertButyldimethylsilyl-N-methyltrifluoroacetamide in a subsequent step. Myristic acid d27 (10 μl, 1.5 mg/ml) was added as an internal standard. The dried samples were reconstituted with a solution of methanol/toluene (333 μl, 1:1 v/v), treated with 0.5 M sodium methoxide (167 μl) and incubated at room temperature for 1 h. The reaction was stopped by the addition of 1 M NaCl (500 μl) and concentrated HCl (25 μl). The fatty acids were extracted with two volumes of hexane (500 μl) and the combined organic layers were dried under N 2 . Samples were then silylated by reconstituting with 40 μl acetonitrile and treating with 40 μl N-tertButyldimethylsilyl-N-methyltrifluoroacetamide (with 1% tert-Butyldimethylchlorosilane) (Thermo), and incubating at 70°C for 60 min. Following derivatization, 2-fluorobiphenyl in anhydrous pyridine (10 μl, 1 mM) was added to the samples as an injection standard and the samples were transferred to deactivated glass vial inserts. The order of sample preparation and analysis on GC-MS was randomized.
GC-MS analysis
GC-MS analysis was performed on an Agilent 7890 GC equipped with a 30-m DB-5MS capillary column with a 10-m Duraguard column connected to an Agilent 5975 MSD operating under electron impact ionization (Agilent Technologies, Stokewood, UK). Samples were injected with an Agilent 7693 autosampler injector into deactivated splitless liners using helium as the carrier gas. Metabolites were assigned using an in-house generated library with the deconvolution programme AMDIS. 63 Individual isotopomer peaks were integrated using MatLab scripts based on the programme GAVIN, 64 to obtain a mass isotopomer distribution vector for each metabolite. Mass isotopomer distributions were normalized such that the sum of the metabolite isotopomer abundances was equal to one, and corrected for naturally occurring elemental isotopes based on the method described by Millard et al.
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Isotopomer spectral analysis Isotopomer spectral analysis was performed with MATLAB scripts developed in-house and provided estimates for three parameters that describe the biosynthesis of fatty acids: the relative enrichment in the lipogenic AcCoA pool from a given 13 C-labelled tracer (D), the fraction of fatty acids that are newly synthesized (g(t)), 38 and the elongation of endogenous fatty acids (Elongation) through the addition of a single AcCoA from the synthesis pool. 39 These parameters were estimated for replicate fatty acid mass isotopomer distributions and parameter errors were verified via parameter sensitivity analysis using a Monte Carlo approach. 66 
Statistical analyses
All summary experimental data are presented as means with error bars indicating s.e.m. A two-sided Student's t-test was used for significance testing where appropriate, unless otherwise stated.
Survival analysis and in vivo correlations
Survival analyses on possible target genes of miR-22 were conducted on breast cancer data sets housed in the Kaplan-Meier Plotter database 67 and TCGA. 43 All gene expression data, apart from the TCGA data set, were downloaded from the GEO database. All gene expression from GEOdb was pre-processed by the GCRMA procedure, which takes into account genespecific binding before quantile normalization. TCGA gene expression data (tier 3 data-log 2 of lowess normalized data) were downloaded from the TCGA data portal. miRNA-seq data from TCGA and Farazi et al. 44 were normalized by trimmed mean of M-values normalization. 68 Survival data were extracted directly from GEOdb, where available. Survival data of the data sets that were not available on GEOdb were extracted from the KaplanMeier Plotter database. 67 The data sets used were GSE1456, GSE16391, GSE2034, GSE2990, GSE3494, GSE6532, GSE7390 and GSE9195. All correlation analyses used Spearman's rank correlation. HRs were calculated using a Cox proportional hazard function dichotomized on upper and lower tertliles of gene and miRNA expression. All data analysis was done in the R statistical environment. Gene expression pre-processing of data sets from GEOdb was done using the 'simpleaffy' package. 69 miRNA-seq data normalization was conducted using the 'edgeR' package. 70 Survival analysis was conducted using the 'survival' package. 71 miRNA target prediction miRNA target prediction algorithms are characterized by high falsepositive and false-negative rates. By combining the results of multiple algorithms, it is possible to reduce the inaccurate predictions of these algorithms. Here we used miRSystem, 72 which combines information from miR-22 regulates tumour metabolism C Koufaris et al Diana-microT, miRanda, miRBridge, rna22, PITA, Pictar and TargetScan miRNA target prediction algorithms. We considered as putative targets of miR-22 to be those predicted by three or more algorithms. The predicted targets for miR-22 can be seen in Supplementary File S1. To identify putative miR-22 metabolic direct targets, we then determined the overlap between genes predicted to be targets of miR-22 by three or more target prediction software and to be repressed by more than 1.5-fold in MCF-7 (Xiong et al.
33
) and ES-2 (Nagaraja et al. 34 ) transfected with the miRNA.
Expression patterns of miR-22
Expression of miR-22 across various adult tissues was determined from independent microarray 73 and next-generation sequencing 74 data sets. Expression data associated with differentiation of cells in vitro were obtained from published studies as indicated in Supplementary Table S1 .
Code availability R scripts used for the analysis of tumour gene expression profiles are publicly available and can be sourced from http://CRAN.R-project.org. The R script used for O2-PLS analysis is available for non-commercial purposes only on request from e.nevedomskaya@nki.nl. MATLAB code for isotopomer spectral analysis is available on request from the authors.
